AVITA Medical Q4 2023 GAAP EPS $(0.28) Beats $(0.38) Estimate, Sales $14.20M Miss $14.50M Estimate
Portfolio Pulse from Benzinga Newsdesk
AVITA Medical (NASDAQ:RCEL) reported Q4 2023 earnings with a GAAP EPS of $(0.28), surpassing the $(0.38) estimate. However, their sales of $14.20M fell short of the $14.50M estimate, marking a 50.13% increase from the previous year.
February 22, 2024 | 9:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
AVITA Medical reported a better-than-expected Q4 2023 GAAP EPS of $(0.28), beating estimates by 26.32%, but missed sales estimates by 2.10%, reporting $14.20M against a $14.50M forecast.
The mixed results from AVITA Medical, with an earnings beat but a slight miss on sales, could lead to a neutral short-term impact on the stock price. The significant year-over-year sales growth might offset concerns about the sales miss, maintaining investor interest.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100